All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@mandy_lea_'s hormone pellet claims need more context

The Mandy Lea

TikTok creator

246.2K viewsWatch on TikTok→

Quick answer

The creator reports a serum testosterone level of 4 ng/dL with symptomatic presentation consistent with androgen deficiency in women, including apparent fatigue and reduced wellbeing, and elected subcutaneous testosterone pellet therapy after inadequate response to topical cream. Her provider deferred estrogen therapy based on FSH results suggesting preserved ovarian function, framing this as a targeted intervention for isolated low androgen rather than full hormone replacement. Pellet-based testosterone delivery in women is not FDA-approved, carries fixed-dose limitations once inserted, and requires careful monitoring to avoid supraphysiologic levels.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @mandy_lea_ actually say?

Sitting in a parking lot post-appointment, @mandy_lea_ shared that her testosterone level came back at "a four" and that she opted for a subcutaneous pellet instead of cream because, in her words, "creams do not do any good for me." Her doctor held off on estrogen for now, pointing to the low testosterone as the likely culprit behind her symptoms. She said the pellet goes in the hip area, lasts roughly three months, and she expects to feel results "in about a week or so."

She was not making sweeping medical claims. This was a personal health update, conversational and honest about uncertainty. But because 246,000 people watched it, the casual details she shared, including the number "four" and the framing around pellets, deserve a closer look.

Does the science back this up?

Partly. The evidence for testosterone therapy in women is real but messier than pellet advocates typically admit. Low testosterone in women is associated with reduced libido, fatigue, and mood changes, symptoms she implied she was experiencing. A 2019 Global Consensus Statement published in the Journal of Clinical Endocrinology and Metabolism (Davis et al.) confirmed that testosterone therapy improves sexual function in postmenopausal women with low desire. That part holds up.

The pellet delivery method is where things get complicated. Unlike injections, patches, or gels, subcutaneous pellets are not FDA-approved for women in the United States. Dosing is harder to adjust once the pellet is inserted, meaning if levels go too high, there is no good way to pull it back. A 2014 study in Maturitas (Glaser and Dimitrakakis) showed pellets can raise testosterone levels significantly, but critics note those same studies reported supraphysiologic levels in some patients. The inability to titrate is a real clinical limitation that does not come up in the video.

What did they get wrong (or right)?

She got the placement right. The pellet goes in the subcutaneous fat of the upper outer buttock or hip, not deep muscle. That is accurate. Her estimate of a three-month duration is also reasonable, with most studies showing pellets lasting 12 to 16 weeks in women depending on dose and metabolism.

The "week or so" timeline for feeling results is optimistic but not outlandish. Testosterone levels typically rise within days of insertion, though subjective symptom improvement often takes two to four weeks.

What she glossed over is the number four itself. A testosterone level of 4 ng/dL in a woman sounds alarming, but reference ranges vary significantly by lab and assay. The Endocrine Society does not have a single agreed-upon lower limit for female testosterone, and some labs flag levels below 15 ng/dL, others below 10 ng/dL. Without knowing the assay used, calling a level of 4 definitively deficient is harder than she implied. This does not mean she was wrong, her symptoms were real, but viewers should not assume a "four" maps neatly onto their own labs.

What should you actually know?

If you are a woman in your 40s exploring hormone therapy, here is what this video does not cover. First, pellets are off-label for women in the US. That is not a reason to refuse them, but it does mean your provider is working outside standard FDA-approved indications, and dosing protocols vary widely between clinics. Second, testosterone levels in women are notoriously difficult to measure accurately at low ranges. The Endocrine Society's 2010 guidelines (Rosner et al., Journal of Clinical Endocrinology and Metabolism) flagged that most immunoassays are not validated for female ranges and that mass spectrometry is more reliable.

Third, skipping estrogen may be the right call for her specifically, especially if her FSH looks good and she is not clearly postmenopausal. But estrogen and testosterone work together in women, and the decision to defer estrogen deserves more explanation than "we're just going to try this first." Her doctor may have excellent reasons. Viewers who take this as a general template may miss something relevant to their own situation.

Pellets are not inherently dangerous, but they are also not the no-brainer convenience story this video tells. Do your homework before you commit to something you cannot easily reverse.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @mandy_lea_'s hormone pellet claims need more context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@mandy_lea_'s hormone pellet claims need more context should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Claim verdict

The useful answer behind this video

Claim being checked

The creator reports a serum testosterone level of 4 ng/dL with symptomatic presentation consistent with androgen deficiency in women, including apparent fatigue and reduced wellbeing, and elected subcutaneous testosterone pellet therapy after inadequate response to topical cream.

FormBlends verdict

The creator reports a serum testosterone level of 4 ng/dL with symptomatic presentation consistent with androgen deficiency in women, including apparent fatigue and reduced wellbeing, and elected subcutaneous testosterone pellet therapy after inadequate response to topical cream. Her provider deferred estrogen therapy based on FSH results suggesting preserved ovarian function, framing this as a targeted intervention for isolated low androgen rather than full hormone replacement. Pellet-based testosterone delivery in women is not FDA-approved, carries fixed-dose limitations once inserted, and requires careful monitoring to avoid supraphysiologic levels.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator reports a serum testosterone level of 4 ng/dL with symptomatic presentation consistent with androgen deficiency in women, including apparent fatigue and reduced wellbeing, and elected subcutaneous testosterone pellet therapy after inadequate response to topical cream. Her provider deferred estrogen therapy based on FSH results suggesting preserved ovarian function, framing this as a targeted intervention for isolated low androgen rather than full hormone replacement. Pellet-based testosterone delivery in women is not FDA-approved, carries fixed-dose limitations once inserted, and requires careful monitoring to avoid supraphysiologic levels.
  • Testosterone therapy for women is supported by a 2019 Global Consensus Statement (Davis et al., Journal of Clinical Endocrinology and Metabolism) specifically for improving sexual function, but evidence for other symptoms like fatigue remains weaker.
  • Subcutaneous testosterone pellets are not FDA-approved for women in the United States. They are used off-label, and dosing cannot be adjusted after insertion if levels run too high.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Testosterone therapy for women is supported by a 2019 Global Consensus Statement (Davis et al., Journal of Clinical Endocrinology and Metabolism) specifically for improving sexual function, but evidence for other symptoms like fatigue remains weaker.
  • Subcutaneous testosterone pellets are not FDA-approved for women in the United States. They are used off-label, and dosing cannot be adjusted after insertion if levels run too high.
  • A testosterone level of 4 ng/dL sounds alarming, but female testosterone is commonly mismeasured at low ranges. The Endocrine Society recommends mass spectrometry over standard immunoassays for accurate results in women.
  • Pellet duration of roughly three months is accurate on average, but individual variation based on dose and metabolism means some women see levels drop earlier or later than that window.
  • Deferring estrogen while starting testosterone may be clinically appropriate for some perimenopausal women with isolated androgen deficiency, but it is not a universal protocol and should be based on individual lab values and symptom profiles.
  • Topical testosterone absorption genuinely varies between individuals, so a personal report of poor cream response is biologically plausible, not just preference.
  • Viewers should not use another person's hormone levels as a reference point for their own. Lab ranges differ by assay and by lab, and symptom interpretation requires clinical context.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

The Mandy Lea · TikTok creator

246.2K views on this video

HRT #pellets #hrt #testosterone #hormonereplacementtherapy #womenshealth #women40plus #40s

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by The Mandy Lea, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.